Next Article in Journal
Assessing Analytical Performance and Correct Classification for Cardiac Troponin Deltas Across Diagnostic Pathways Used for Myocardial Infarction
Previous Article in Journal
Periodontal Disease Elevates IL-6 Levels During Initial Symptoms of COVID-19
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Interesting Images

Central Airway Carcinoid Tumorlets Following Resection of a Typical Carcinoid Tumor

1
Department of Radiology, Institute of Medical Science, School of Medicine, Gyeongsang National University, Jinju 52727, Republic of Korea
2
Department of Radiology, Gyeongsang National University Changwon Hospital, Changwon 51472, Republic of Korea
3
Department of Internal Medicine, School of Medicine, Gyeongsang National University, Gyeongsang National University Changwon Hospital, Changwon 51472, Republic of Korea
4
Department of Pathology, School of Medicine, Gyeongsang National University, Gyeongsang National University Changwon Hospital, Changwon 51472, Republic of Korea
*
Author to whom correspondence should be addressed.
Diagnostics 2025, 15(13), 1651; https://doi.org/10.3390/diagnostics15131651
Submission received: 21 May 2025 / Revised: 20 June 2025 / Accepted: 27 June 2025 / Published: 28 June 2025
(This article belongs to the Section Medical Imaging and Theranostics)

Abstract

Pulmonary neuroendocrine proliferations and neoplasms represent a broad spectrum of diseases, ranging from neuroendocrine cell hyperplasia and tumorlets to carcinoid tumors. Carcinoid tumorlets are most commonly located in the peripheral airways and are often incidentally detected as pulmonary micronodules on chest CT. We report the radiological, bronchoscopic, and pathological findings of a case of carcinoid tumorlets presenting as endobronchial nodules in the left main bronchus. The patient had previously undergone a left lower lobectomy five years earlier for a typical carcinoid tumor. Follow-up imaging revealed new endobronchial nodules, which were subsequently confirmed as carcinoid tumorlets through histopathologic analysis. This case highlights the rare presentation of carcinoid tumorlets in the central airways, emphasizing the importance of recognizing their potential for late recurrence and atypical localization. It underscores the necessity for physicians to be aware that pulmonary neuroendocrine tumors can recur over the long term and may present in a multicentric fashion within the disease spectrum.

Figure 1. CT, PET/CT, and bronchoscopic images of a typical carcinoid tumor in the left lower lobe in a 40-year-old man. The patient reported experiencing intermittent blood-tinged sputum, which had started three months before presentation. He had a 20 pack-year smoking history and was on medication for hypertension. (a) Chest CT revealed a well-enhancing nodule measuring approximately 2.5 cm, located in the left lower lobe bronchus (arrow). (b) FDG-PET/CT showed the lesion to be mildly hypermetabolic, with an SUVmax of 2.6 (arrow). (c) Bronchoscopy identified a hypervascular, polypoid lesion obstructing the left lower lobe bronchus. A bronchoscopic biopsy indicated a carcinoid tumor. The patient subsequently underwent video-assisted thoracoscopic surgery (VATS) for a left lower lobectomy.
Figure 1. CT, PET/CT, and bronchoscopic images of a typical carcinoid tumor in the left lower lobe in a 40-year-old man. The patient reported experiencing intermittent blood-tinged sputum, which had started three months before presentation. He had a 20 pack-year smoking history and was on medication for hypertension. (a) Chest CT revealed a well-enhancing nodule measuring approximately 2.5 cm, located in the left lower lobe bronchus (arrow). (b) FDG-PET/CT showed the lesion to be mildly hypermetabolic, with an SUVmax of 2.6 (arrow). (c) Bronchoscopy identified a hypervascular, polypoid lesion obstructing the left lower lobe bronchus. A bronchoscopic biopsy indicated a carcinoid tumor. The patient subsequently underwent video-assisted thoracoscopic surgery (VATS) for a left lower lobectomy.
Diagnostics 15 01651 g001
Figure 2. Gross and microscopic findings of a typical carcinoid tumor. (a) Gross examination of the left lower lobectomy specimen showed a well-demarcated 2.5 cm × 1.0 cm nodule (arrows) within the left lower lobar bronchus. (b) Microscopic examination (× 200) revealed neuroendocrine cell proliferation with inconspicuous, round, bland-looking nuclei, and no evidence of necrosis. There was 1 mitosis per 2 mm2. (ce) Immunohistochemical staining was positive for chromogranin, CD56, and synaptophysin. (f) The Ki-67 index was less than 5%. The lesion was ultimately diagnosed as a typical carcinoid tumor. No lymph node metastasis was observed. The patient remained stable with annual CT follow-ups. However, in the fifth-year post-operation, abnormal findings were detected on chest CT.
Figure 2. Gross and microscopic findings of a typical carcinoid tumor. (a) Gross examination of the left lower lobectomy specimen showed a well-demarcated 2.5 cm × 1.0 cm nodule (arrows) within the left lower lobar bronchus. (b) Microscopic examination (× 200) revealed neuroendocrine cell proliferation with inconspicuous, round, bland-looking nuclei, and no evidence of necrosis. There was 1 mitosis per 2 mm2. (ce) Immunohistochemical staining was positive for chromogranin, CD56, and synaptophysin. (f) The Ki-67 index was less than 5%. The lesion was ultimately diagnosed as a typical carcinoid tumor. No lymph node metastasis was observed. The patient remained stable with annual CT follow-ups. However, in the fifth-year post-operation, abnormal findings were detected on chest CT.
Diagnostics 15 01651 g002
Figure 3. Follow-up CT images obtained in the fifth-year post-operation. (a,b) Chest CT revealed several tiny nodular densities in the left main bronchus (arrows). Although the possibility of bronchial secretions was initially considered, the lesions persisted on a 3-month follow-up CT. (c) A coronal thick slab reformatted image provided a clearer view of multiple nodular lesions, each measuring less than 5 mm (red circle).
Figure 3. Follow-up CT images obtained in the fifth-year post-operation. (a,b) Chest CT revealed several tiny nodular densities in the left main bronchus (arrows). Although the possibility of bronchial secretions was initially considered, the lesions persisted on a 3-month follow-up CT. (c) A coronal thick slab reformatted image provided a clearer view of multiple nodular lesions, each measuring less than 5 mm (red circle).
Diagnostics 15 01651 g003
Figure 4. Bronchoscopy confirmed multiple polypoid lesions in the left main bronchus, each measuring less than 5 mm.
Figure 4. Bronchoscopy confirmed multiple polypoid lesions in the left main bronchus, each measuring less than 5 mm.
Diagnostics 15 01651 g004
Figure 5. Pathologic findings of one of resected endobronchial nodules (×40). (a) A nodular lesion measuring approximately 1.5 mm showed neuroendocrine proliferation. Multiple papillary stalks with single-layered pseudostratified columnar cells with a relatively bland appearance were observed. Two mitoses per 2 mm2 were noted. (bd) The nodule demonstrated positive immunohistochemical staining for chromogranin, CD56, and synaptophysin. (e) The Ki-67 index is approximately 6%. A diagnosis of carcinoid tumorlets was established. Pulmonary neuroendocrine proliferation can be divided into a spectrum of lesions that range from neuroendocrine cell hyperplasia to tumorlets and carcinoid tumors [1,2,3]. Carcinoid tumorlets are nodular neuroendocrine cell aggregates that extend beyond the basement membrane and measure 5 mm or less in size, with histomorphological features similar to carcinoid tumors [4]. Due to their small size, tumorlets are easily overlooked, leading to an underestimation of their true incidence. Tumorlets are typically located in the peripheral airways and appear as pulmonary micronodules on chest CT, resembling metastatic nodules or granulomas [5,6,7]. They are often discovered during histopathological examination of lung tissue resected for other reasons such as lung cancer [6]. Our case demonstrated bronchoscopic and CT findings of carcinoid tumorlets in the left main bronchus, along with corresponding pathological features. Reports of carcinoid tumorlets in the central airways are exceedingly rare, with only a few cases documented in the literature [8,9,10]. In our case, multiple tumorlets were observed five years after surgery for a typical bronchial carcinoid. Multicentric carcinoid tumors or tumorlets are not commonly encountered in clinical practice. However, a long-term observational study of 123 patients reported that approximately 12% of bronchial carcinoid cases exhibited multicentric manifestations, either as carcinoid tumors or tumorlets [11]. For patients with pulmonary carcinoids without distant metastases, surgery involving the complete removal of the primary tumor and a systematic lymph node dissection is recommended as the primary curative treatment. Pulmonary carcinoids may recur late, many years and even decades after treatment [2,12]. To detect late disease progression and recurrence, long-term follow-up using low dose chest CT is necessary [12]. Recurrence and poor prognosis are associated with atypical histology, lymph node metastases at diagnosis, presence of multiple carcinoid tumors or tumorlets, and genetic abnormalities, including large chromosomal alterations, specific gene mutations, and dysregulation of key oncogenic pathways [2,11,13]. The pathogenesis of multiple endobronchial tumorlets in this case remains uncertain. One possible explanation is recurrence of the previous typical carcinoid tumor through intramucosal spread, given that both the initial tumor and the subsequent tumorlets were in the left bronchus. Alternatively, they may represent a delayed manifestation of multicentric carcinoid tumors and tumorlets, supported by the established histogenetic relationship between these entities [11,12]. This case highlights an unusual presentation of carcinoid tumorlets in the central airways, emphasizing the importance of recognizing their potential for recurrence and atypical localization. It underscores the necessity for physicians to be aware that pulmonary neuroendocrine tumors can recur over the long term and may present in a multicentric fashion within the disease spectrum.
Figure 5. Pathologic findings of one of resected endobronchial nodules (×40). (a) A nodular lesion measuring approximately 1.5 mm showed neuroendocrine proliferation. Multiple papillary stalks with single-layered pseudostratified columnar cells with a relatively bland appearance were observed. Two mitoses per 2 mm2 were noted. (bd) The nodule demonstrated positive immunohistochemical staining for chromogranin, CD56, and synaptophysin. (e) The Ki-67 index is approximately 6%. A diagnosis of carcinoid tumorlets was established. Pulmonary neuroendocrine proliferation can be divided into a spectrum of lesions that range from neuroendocrine cell hyperplasia to tumorlets and carcinoid tumors [1,2,3]. Carcinoid tumorlets are nodular neuroendocrine cell aggregates that extend beyond the basement membrane and measure 5 mm or less in size, with histomorphological features similar to carcinoid tumors [4]. Due to their small size, tumorlets are easily overlooked, leading to an underestimation of their true incidence. Tumorlets are typically located in the peripheral airways and appear as pulmonary micronodules on chest CT, resembling metastatic nodules or granulomas [5,6,7]. They are often discovered during histopathological examination of lung tissue resected for other reasons such as lung cancer [6]. Our case demonstrated bronchoscopic and CT findings of carcinoid tumorlets in the left main bronchus, along with corresponding pathological features. Reports of carcinoid tumorlets in the central airways are exceedingly rare, with only a few cases documented in the literature [8,9,10]. In our case, multiple tumorlets were observed five years after surgery for a typical bronchial carcinoid. Multicentric carcinoid tumors or tumorlets are not commonly encountered in clinical practice. However, a long-term observational study of 123 patients reported that approximately 12% of bronchial carcinoid cases exhibited multicentric manifestations, either as carcinoid tumors or tumorlets [11]. For patients with pulmonary carcinoids without distant metastases, surgery involving the complete removal of the primary tumor and a systematic lymph node dissection is recommended as the primary curative treatment. Pulmonary carcinoids may recur late, many years and even decades after treatment [2,12]. To detect late disease progression and recurrence, long-term follow-up using low dose chest CT is necessary [12]. Recurrence and poor prognosis are associated with atypical histology, lymph node metastases at diagnosis, presence of multiple carcinoid tumors or tumorlets, and genetic abnormalities, including large chromosomal alterations, specific gene mutations, and dysregulation of key oncogenic pathways [2,11,13]. The pathogenesis of multiple endobronchial tumorlets in this case remains uncertain. One possible explanation is recurrence of the previous typical carcinoid tumor through intramucosal spread, given that both the initial tumor and the subsequent tumorlets were in the left bronchus. Alternatively, they may represent a delayed manifestation of multicentric carcinoid tumors and tumorlets, supported by the established histogenetic relationship between these entities [11,12]. This case highlights an unusual presentation of carcinoid tumorlets in the central airways, emphasizing the importance of recognizing their potential for recurrence and atypical localization. It underscores the necessity for physicians to be aware that pulmonary neuroendocrine tumors can recur over the long term and may present in a multicentric fashion within the disease spectrum.
Diagnostics 15 01651 g005

Author Contributions

Conceptualization, K.N.J.; methodology, K.N.J., K.B. and H.J.A.; validation, K.N.J., K.B., IR.H., H.J.A. and D.H.S.; formal analysis, K.B., IR.H., H.J.A.; investigation, K.B. and K.N.J.; resources, IR.H., H.J.A. and D.H.S.; data curation, K.N.J., H.J.A. and D.H.S.; writing—original draft preparation, K.B.; writing—review and editing, K.N.J.; visualization, IR.H., H.J.A. and D.H.S.; super-vision, K.N.J. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Gyeongsang National University Changwon Hospital (protocol code 2025-01-021, date of approval: 24 January 2025).

Informed Consent Statement

Written informed consent has been obtained from the patient to publish this paper.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Noguchi, M.; Furukawa, K.T.; Morimoto, M. Pulmonary neuroendocrine cells: Physiology, tissue homeostasis and disease. Dis. Model. Mech. 2020, 13, dmm046920. [Google Scholar] [CrossRef]
  2. Granberg, D.; Juhlin, C.C.; Falhammar, H.; Hedayati, E. Lung Carcinoids: A Comprehensive Review for Clinicians. Cancers 2023, 15, 5440. [Google Scholar] [CrossRef] [PubMed]
  3. Rekhtman, N. Lung neuroendocrine neoplasms: Recent progress and persistent challenges. Mod. Pathol. 2022, 35 (Suppl. S1), 36–50. [Google Scholar] [CrossRef] [PubMed]
  4. Sun, T.Y.; Hwang, G.; Pancirer, D.; Hornbacker, K.; Codima, A.; Lui, N.S.; Raj, R.; Kunz, P.; Padda, S.K. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: Clinical characteristics and progression to carcinoid tumour. Eur. Respir. J. 2022, 59, 2101058. [Google Scholar] [CrossRef] [PubMed]
  5. Ginsberg, M.S.; Akin, O.; Berger, D.M.; Zakowski, M.F.; Panicek, D.M. Pulmonary tumorlets: CT findings. Am. J. Roentgenol. 2004, 183, 293–296. [Google Scholar] [CrossRef] [PubMed]
  6. Aubry, M.C.; Thomas, C.F.; Jett, J.R., Jr.; Swensen, S.J.; Myers, J.L. Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: Analysis of 28 patients. Chest 2007, 131, 1635–1643. [Google Scholar] [CrossRef] [PubMed]
  7. Maki, Y.; Okada, K.; Nakamura, R.; Hirano, Y.; Fujiwara, T.; Yamasaki, R.; Ichimura, K.; Matsuura, M. A case of multiple lung carcinoid tumors localized in the right lower lobe. Respir. Med. Case Rep. 2022, 38, 101679. [Google Scholar] [CrossRef]
  8. De Giorgi, U.; Fanini, F.; Amadori, D.; Cancellieri, A.; Fiorentini, G.; Poletti, V.; Barzon, L.; Masi, G. Tumorlets in familial history of bronchopulmonary carcinoid. J. Thorac. Oncol. 2011, 6, 1613–1614. [Google Scholar] [CrossRef] [PubMed]
  9. Popovic, M.; Tegeltija, D.; Popovic, A.; Lecic, S.K.; Lovrenski, A. An Unusual Finding of Tumorlet Carcinoid and Endobronchial Hamartoma in the Lobar Bronchus. Int. J. Morphol. 2022, 40, 990–994. [Google Scholar] [CrossRef]
  10. Pandey, A.; Bargunam, P.; Saini, M.; Kundu, S.; Sharma, M. Carcinoid tumorlet/typical carcinoid of the lung: An incidental bronchoscopic finding and cytological dilemma. J. Assoc. Chest Physicians 2024, 12, 33–39. [Google Scholar] [CrossRef]
  11. Ferolla, P.; Daddi, N.; Urbani, M.; Semeraro, A.; Ribacchi, R.; Giovenali, P.; Ascani, S.; De Angelis, V.; Crino, L.; Puma, F.; et al. Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids. J. Thorac. Oncol. 2009, 4, 383–387. [Google Scholar] [CrossRef] [PubMed]
  12. Baudin, E.; Caplin, M.; Garcia-Carbonero, R.; Fazio, N.; Ferolla, P.; Filosso, P.L.; Frilling, A.; de Herder, W.W.; Hörsch, D.; Knigge, U.; et al. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2021, 32, 439–451. [Google Scholar] [CrossRef] [PubMed]
  13. Miyanaga, A.; Masuda, M.; Motoi, N.; Tsuta, K.; Nakamura, Y.; Nishijima, N.; Watanabe, S.I.; Asamura, H.; Tsuchida, A.; Seike, M.; et al. Whole-exome and RNA sequencing of pulmonary carcinoid reveals chromosomal rearrangements associated with recurrence. Lung Cancer 2020, 145, 85–94. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Bae, K.; Jeon, K.N.; Heo, I.R.; An, H.J.; Song, D.H. Central Airway Carcinoid Tumorlets Following Resection of a Typical Carcinoid Tumor. Diagnostics 2025, 15, 1651. https://doi.org/10.3390/diagnostics15131651

AMA Style

Bae K, Jeon KN, Heo IR, An HJ, Song DH. Central Airway Carcinoid Tumorlets Following Resection of a Typical Carcinoid Tumor. Diagnostics. 2025; 15(13):1651. https://doi.org/10.3390/diagnostics15131651

Chicago/Turabian Style

Bae, Kyungsoo, Kyung Nyeo Jeon, I Re Heo, Hyo Jung An, and Dae Hyun Song. 2025. "Central Airway Carcinoid Tumorlets Following Resection of a Typical Carcinoid Tumor" Diagnostics 15, no. 13: 1651. https://doi.org/10.3390/diagnostics15131651

APA Style

Bae, K., Jeon, K. N., Heo, I. R., An, H. J., & Song, D. H. (2025). Central Airway Carcinoid Tumorlets Following Resection of a Typical Carcinoid Tumor. Diagnostics, 15(13), 1651. https://doi.org/10.3390/diagnostics15131651

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop